Corticotropin-releasing hormone (CRH) is a key neuroendocrine factor implementing endocrine, immune and behavioral responses to stress. CRH exerts its action through two major receptors, CRH-R1 and CRH-R2. Recently novel non-peptidic antagonists directed against CRH-R1 or CRH-R2 have been proposed as promising agents in the treatment of depression, anxiety and eating disorder. However, so far the CRH-receptor system has not been widely studied in humans. Therefore, we employed quantitative TaqMan PCR to analyze the expression and distribution of both CRH-R1 and CRH-R2 in human brain tissue and peripheral organs. Furthermore the expression of CRH receptors was analyzed for the first time in pituitaries of suicide victims by in situ hybridization and quantitative PCR. Our data demonstrated a different expression pattern in humans as compared to rodents. Both CRH-R1 and CRH-R2 were expressed in high amounts in the brain with the strongest expression in the pituitary. As described in rodents, however the CRH-R1 in human was the predominant receptor in the brain (82.7 ± 11.0%), whilst CRH-R2 was the predominant receptor in peripheral organs (77.0 ± 15.8%). There was a shift in the ratio of CRH-R1/R2 in the pituitaries of suicide victims. In conclusion, both CRH-R1 and CRH-R2 are widely expressed in human tissues with a distribution substantially different from rodents. Strong expression of both CRH-R1 and CRH-R2 in human pituitaries suggests that particularly under stress, activation of the HPA axis can be maintained through both receptors. Molecular Psychiatry (2001) 6, 540-546.
Introduction
Corticotropin-releasing hormone (CRH) is the principal hypothalamic factor involved in the regulation of the hypothalamic-pituitary-adrenal (HPA) axis. 1, 2 CRH exerts its actions by binding to specific cell surface receptors on its target tissues. 3, 4 Two different families of CRH receptors, CRH receptor type I (CRH-R1) and CRH receptor type II (CRH-R2), have been cloned from human tissue. [5] [6] [7] [8] [9] The R1 type presents greater selectivity for CRH, while the R2 receptor exhibits preferential selectivity for the CRH-like peptides, including urotensin and urocortin. In rodents, CRH-R1 are most abundant in neocortical, cerebellar, and sensory relay structures whereas CRH-R2 are predominantly localized in specific subcortical areas and peripheral tissues. 3, [10] [11] [12] CRH activates the HPA axis through CRH-R1 expressed on pituitary adenotroph cells and the CRHinduced release of ACTH can be blocked by selective CRH-R1 antagonists in rats. 13, 14 This tissue distribution seems to be different in nonhuman primates. In contrast to the previously described neuroendocrine distribution in rat, CRH-R2 and CRH-R1 were detected in the primate anterior pituitary. 15 CRH-R1 antagonists had only a minor inhibitory effect on pituitary ACTH release in primates and no effect on ACTH or cortisol release in humans. 16, 17 Mental disorders, including major depression and other anxiety studies, have been associated with a dysregulation of the HPA axis and an altered expression of CRH in the hypothalamus. 18 CRH has the capacity to trigger the major behavioral, neuroendocrine, autonomic, and neurovegetative responses to stress. 2, 19 Studies employing antisense oligodeoxynucleotides in rats directed against CRH-R1 or CRH-R2 identified the CRH-R1, as the main target for CRH mediating anxiogenesis. 20 However, recent data suggest that in response to stressful stimuli, or after local injection of high CRH doses, CRH-R2 mediates anxiety. Hippocampal CRH-R1 is involved in the enhancement of stressinduced learning, whereas CRH-R2 of the lateral intermediate septum mediates tonic impairment of learning. 1 Furthermore, CRH-R2 is involved in the CRH effects on food intake and in sexual female behavior.
Based on these findings, it has been suggested that patients suffering from anxiety and depression may benefit from treatment with CRH-R1 antagonistic drugs, while drugs targeting CRH-R2 may be of benefit for patients with eating disorders. [20] [21] [22] Indeed, oral administration of novel nonpeptidic CRH-R1 antagonists significantly attenuated behavioral, neuroendocrine, and autonomic responses to stress in primates and reduced depression and anxiety scores in a first trial in patients with melancholic depression. 16, 17 Considering the potential of CRH receptor antagonism in the treatment of stress-related disorders, it is surprising that the human CRH-receptor system has not been studied in detail. Therefore, we analyzed the expression of CRH-R1 and CRH-R2 in human tissues using the novel technique of quantitative, Taqman PCR. The expression of CRH receptors in pituitaries of suicidal and control individuals was analyzed by in situ hybridization and Taqman PCR.
Material and methods

Human tissues
Normal human tissue (amygdala, thalamus, pituitary, hippocampus, cerebellum and substantial nigra, heart, lung, skeletal muscle, stomach, liver, kidney, adrenal and placenta) of individuals aged 17-72 years was used for RNA isolation. Three different RNA samples from a male/female pool of 20-60 individuals each were tested (Clontech Lab, Palo Alto, CA, USA). The cause of death included trauma or sudden death due to cardiovascular failure. In addition, nine post-mortem pituitaries (three males and six females) were collected from suicide victims (generously provided by Dr WW Tourtellote, National Neurological Research Specimen Bank, Los Angeles, CA, USA) and seven post-mortem pituitaries (four males and three females) were collected from control subjects (generously provided by National Disease Research Interchange, Philadelphia, PA, USA). The study was approved by the institutional review board of each center. Mean age was 36.8 ± 7.1 and 48.71 ± 9.8 years (mean ± SEM; P = 0.7) respectively for suicide victims and controls.
Taqman PCR
RT-PCR experiments were carried out according to the thermoscript RT-PCR system kit for RT-PCR instructions provided by the manufacturer (Gibco, Gaithersburg, MD, USA). Total RNA (1 g) of human pituitary gland and mRNAs (1 g) of human brain and peripheral tissue, were reverse transcribed to complementary DNA (cDNA) by a reaction containing 2 mM deoxynucleotide mix, 100 mM DTT, 40 units RNase inhibitor, 50 ng random primer and 15 units thermoscript reverse transcriptase. The reaction was run at 25°C for 10 min and 50°C for 50 min, heated at 85°C for 5 min, and then cooled to 4°C.
To quantify the expression of CRH-R1 and CRH-R2, we applied the Taqman PCR using the 7700 Sequence Detector (Perkin Elmer Applied Biosystems, Foster, CA, USA). Reactions contained 1× Taqman Universal Molecular Psychiatry PCR Master Mix, 900 nM of forward and reverse primers for CRH1R and CRH2R, (CRH-R1 sense: 5Ј-CGCATCCTCATGACCAAGCT-3Ј, antisense: 5Ј-TCA CAGCCTTCCTGTACTGAATG-3Ј and CRH-R2 sense: 5Ј-CCCGGGCCATGTCCAT-3Ј, antisense: 5Ј-ACAGCGG CCGTCTGCTT-3Ј, and 200 nM of Taqman probes (CRH1R: 5Ј-CGGGCATCCACCACGTCTGAGA-3Ј, CRH2R: 5Ј-CTACATCACCCACACGGCTCAGCTTCC-3Ј). 18S primers and probe were added at 50 nM. Thermal cycling proceeded with 50 cycles of 95°C for 15 s and 60°C for 1 min. Input RNA amounts were calculated with relative standard curves for both the mRNAs of interest (CRH-R1 and CRH-R2) and 18S.
In situ hybridization histochemistry Post-mortem tissues were stored at −70°C prior to processing for in situ hybridization. A ribonucleotide probe, directed against the human CRH-R1 sequence, was generated from a subclone of the human CRH-R1 cDNA 1 (kindly provided by W Vale, The Salk Institute for Biological Studies, La Jolla, CA, USA) containing only coding sequence. Transcription of antisense and sense probes was carried out using the Riboprobe System (Promega Biotech, Madison, WI, USA) in the presence of [␣- 35 S] UTP (sp. act. 1000-1500 Ci mmol −1 , New England Nuclear, Boston, MA, USA).
Sectioning, fixing, ISHH, autoradiography, and anatomical localization of the probe at the cellular level were performed as described by Wong et al. 23 Approximately 5 × 10 5 cpm of radiolabeled probe per 50 l hybridization buffer were used. Fifty microliters of hybridization buffer were applied on each section, which was then covered by coverslip. Hybridization was carried out at 55°C for 18 h. After hybridization, slides were treated with RNAse A; washed sequentially up to 0.2 × SSC at 60°C; dehydrated, and air-dried. Hybridization and post-hybridization treatments were concomitantly carried out on antisense and control sections. Sections were exposed to X-ray film (Hyperfilm B max, Amersham Corp, Arlington Heights, IL, USA) for 10-15 days. The films were developed in D19 (Eastman Kodak Co, Rochester, NY, USA) for 5 min at 20°C. Anatomical localization of the probe at the cellular level was performed by dipping the slides into NTB-2 nuclear track emulsion (Eastman Kodak Co) diluted 1:1 with distilled water, developed after 8 weeks of exposure, and counterstained with cresyl violet. The localization of grains was studied with light microscopy (Leitz, Wetzlar, Germany). A sense probe was used to control specificity of the probe and the hybridization method.
Quantification of mRNA levels for CRHR-R1 was done using a Macintosh-based image analysis program (NIH IMAGE version 1.55).
Results
Quantitative expression of CRH-R1 and CRH-R2 mRNA in human tissues
The expression of CRH-R1 and CRH-R2 mRNA was analyzed by Taqman PCR in human brain tissues (amygdala, thalamus, pituitary, hippocampus, cerebellum and substantia nigra) and human peripheral organs (heart, lung, skeletal muscle, stomach, liver, kidney, adrenal and placenta) (Figure 1 ). The expression of both CRH-R1 and CRH-R2 mRNA was significantly higher in brain tissues than in peripheral organs. On Figure 1 TaqMan PCR of CRH-R1 and CRH-R2 mRNA in human tissues. The expression of CRH-R1 and CRH-R2 is significantly higher in the pituitary gland as compared to other brain tissues (a,c). In the peripheral tissues, the highest expression of CRH-R1 mRNA was found in lung and skeletal muscle (b). CRH-R2 is expressed most prominently in the heart (d). Data represent the mean ± SEM. CRH-R1 and CRH-R2 expression levels are compared to either substantia nigra (a,c) or stomach (b,d) .
average CRH-R1 expression was 21 000 times higher in brain tissue (Figure 1a ) than in peripheral organs (Figure 1b) , whereas CRH-R2 was 44 times higher in the brain (Figure 1c ) as compared to the periphery (Figure 1d ). In the human brain, both CRH-R1 and CRH-R2 were found in the amygdala, thalamus, pitu-itary and hippocampus. CRH-R1 was also present in the cerebellar cortex and at a very low level in the substantia nigra. There was no expression of CRH-R2 in these structures. Both CRH-R1 and -R2 demonstrated the strongest expression within the pituitary (Figure 1a, c) .
In the peripheral tissue, both CRH-R1 and CRH-R2 were expressed in the heart, lung, skeletal muscle, stomach, kidney, adrenal and placenta. CRH-R2 exhibited a weak expression in liver but CRH-R1 was not expressed in this tissue. CRH-R1 was most prominently expressed in the skeletal muscle, lung and adrenals (Figure 1b) , whereas CRH-R2 demonstrated by far the strongest expression in the heart (Figure 1d) .
The comparison of the relative distribution of CRH-R1 and -R2 in each tissue demonstrated that the ratio of R1 to R2 in the amygdala, hippocampus and pituitary was 2.4-3.9 to 1 and in the thalamus 12.4 to 1 (Figure 2 ). In peripheral tissues there was an inverse relationship with a 1.2-4.2 to 1 ratio of CRH-R2 to -R1 within the adrenal, placenta, kidney and lung and 22.9 to 1 ratio in the heart (Figure 2 ).
Quantitative expression of CRH-R1 and CRH-R2 in pituitaries of suicide victims and controls
The pituitary demonstrated the strongest expression of both CRH-R1 and CRH-R2. The expression levels of CRH-R1 mRNA as determined by Taqman PCR and in situ hybridization did not show a significant difference. Control hybridization with labeled sense riboprobe produced a uniform, low signal, which was barely visible on film. We found that CRH-R1 mRNA in the post-mortem pituitary tissue obtained from suicide and control subjects was not significantly different as determined by in situ hybridization (438.4 ± 19.9 and 451.1 ± 18.8 DPM (mean ± SEM), respectively, P = 0.7) (Figure 3 ) and as determined by Taqman PCR (100 ± 21.2 and 190.7 ± 66.1% (mean ± SEM), respectively, P = 0.2) (Figure 4a ). Also the expression of CRH-R2 as determined by Taqman PCR was not significantly Figure 2 Comparison of the distribution of CRH-R1 and CRH-R2 in human tissues. In the brain tissues CRH-R1 is the predominant receptor, whereas CRH-R2 is the predominant receptor in peripheral organs. Data represent the mean ± SEM.
Molecular Psychiatry different between the two groups (100 ± 9.6 and 74.4 ± 11.6% (mean ± SEM), respectively, P = 0.2) (Figure 4b ). However, there was a significant shift in the ratio of CRH-R1/R2 in suicide victims compared to normal individuals (4.65 ± 1.85 and 9.64 ± 3.80 (mean ± SEM), respectively, P Ͻ 0.05) (Figure 4c ).
Discussion
CRH is a key regulator in the coordination of neuroendocrine, autonomic and behavioral responses to stress. 2, 18, 24, 25 Biological diversity and selectivity of the CRH-system is based on multiple endogenous ligands and receptors. [10] [11] [12] 19 Similar to previous work in rodents, our present study demonstrates that CRH-R1 and CRH-R2 are widely distributed in human brain and peripheral tissues. Our data confirm in humans the general distribution described in rats with CRH-R1 being the major receptor in the brain and CRH-R2 being the predominant receptor in peripheral tissues. 4, 23, 26 However in the human brain, both CRH-R1 and CRH-R2 were found in the cortex, pituitary, amygdala, hippocampus, thalamus and cerebellum, suggesting that the CRH-R2 subtype is distributed more broadly and at a higher level in the human brain than in rats. Unlike in rat pituitaries that do not express CRH-R2, both CRH-R1 and CRH-R2 are expressed in high amounts in control human pituitaries. This provides an explanation for the failure of CRH-R1 antagonists to block the release of ACTH from the pituitary in humans. 17 In mice or rats, CRH-R1 are critical for the CRH-mediated activation of the HPA axis. Deletion of CRH-R1 in mice leads to an impairment of the pituitary-adrenal stress response. 27, 28 Treatment of rats with the CRH-R1 antagonist Antalarmin, blunted the CRH-mediated ACTH release. 13 The high expression of CRH-R2 in human pituitaries suggests that even under CRH-R1 blockade, an appropriate ACTH release can be achieved through CRH-R2. In CRH-R2 deficient mice, it has been recently shown that although initiation of the stress response appears to be normal, CRH-R2 is involved in maintaining HPA drive. 29 Urocortin, recently identified in the rat brain as a neuropeptide of the CRH family has been demonstrated to bind strongly to CRH-R2. Synthetic urocortin is a potent stimulator of ACTH secretion from rat pituitary cells both in primary culture and in vivo. Urocortin stimulates ACTH secretion from rat pituitary cells with equal efficiency to CRH. 30 Urocortin is abundantly expressed in the human pituitary gland. 30 Therefore in humans, both CRH-R1 and CRH-R2 should be able to mediate activation of the pituitary-adrenal axis.
We also found a significant expression of CRH-R1 and CRH-R2 in the human adrenals. 31 This confirms previous reports demonstrating a local CRH/ACTH system in the adrenal medulla. Thus, CRH was shown to stimulate cortisol production in cortical and chromaffin cell co-cultures. This effect could be blocked by the selective CRH-receptor antagonist, suggesting that CRH-R1 are primarily involved in an intraadrenal CRH/ACTH control system in humans. Altogether, these data underline the built-in redundancy of the CRH-system in the human HPA axis.
CRH has been implicated in modulating a wide variety of physiological and pathophysiological responses, including the immune system and inflammation, 2, 32 energy balance and obesity, 33 and intestinal motility. 34 CRH activates mast cells via CRH-R1, leading to release of histamine and hence, vasodilation and increased vascular permeability. Thus activation of the immune system through CRH may influence the susceptibility of an individual to autocrine, allergic, infectious or neoplastic diseases. 2 Evidence that skin cells both produce CRH and express functional CRH-R1 supports the existence of a local CRH/CRH-R neuroendocrine pathway that may be activated with the context of a skin stress response system. 35 As reported previously in rodents 4 CRH-R2 is strongly expressed in the human heart and impaired cardiovascular function has been reported in mice lacking the CRH-R2 receptor. 29 Therefore in humans, cardiac actions of CRH may also be mediated through the CRH-R2 receptor. Finally, the CRH-system with its numerous clusters of brain neurons, its closely related peptide urocortin, and its two receptor types widely distributed throughout the brain, forms a network of neuronal pathways capable of interacting with the centers in the brain controlling food intake and energy expenditure. 33 Based on these data, CRH-R1 antagonists have been proposed as antiinflammatory agents and R2 antagonists have been suggested to be potentially beneficial for eating disorders. 2, 20 However, data derived from studies in mice and rats, may not be easily translated to humans.
CRH has also been shown to play a significant role in the acquisition and storage of classically conditioned fear responses in the amygdala. Descending hypothalamic CRH pathways to brainstem noradrenergic nuclei also contribute to arousal and activation of the sympathetic nervous system. 33 Thus, the central administration of CRH to rodents and primates not only promotes activation of the HPA axis, but also sets into motion a sequence of behavioral and physiological events that closely resemble those in melancholic depression and stress. 26 Depression is the main cause of suicide: about 70% of all suicides are attributed to untreated depression. Studies in the United States suggest that at any given time, approximately 2-3% of the population is hospitalized or seriously impaired by affective illness. Individuals who commit suicide frequently suffer from depression and will have an activated HPA axis. 36 In fact, hyperplastic adrenals have been described both in depressed patients and suicide victims, and suicide victims had higher POMC mRNA density per cell and larger corticotrophic cell size than cardiac death victims. [36] [37] [38] In patients with melancholic depression and anxiety disorders, an increased expression of hypothalamic CRH mRNA has been described and CSF CRH levels are inappropriately elevated for their degree of hypercortisolism. 26 However, our results did not demonstrate any significant changes in the quantitative expression of CRH-receptors in pituitaries of suicide victims as compared to controls. Considering the fact that in these patients high CRH levels have been reported, one may have expected a downregulation of the CRH-R1, therefore normal expression in the presence of an activation of the HPA axis may reflect an inappropriate stimulation of the receptor system. Interestingly, there is a significant shift in the ratio of the CRH-R1 and CRH-R2 in the pituitary of the depressed patients. This means that the activation of the HPA axis in these patients may occur even more strongly through the CRH-R2 system. Therefore treatment with the CRH-R1 antagonists will Molecular Psychiatry Figure 4 TaqMan PCR of CRH-R1 and CRH-R2 mRNA in normal pituitaries and pituitaries of suicide victims. The expression of CRH-R1 and CRH-R2 mRNA in pituitaries obtained from suicide and control patients is not significantly different (a,b). The ratio of CRH-R1/R2 for control pituitary is higher than for suicide victims (c). Data represent the mean ± SEM. CRH-R1 and CRH-R2 expression levels are compared to suicide. ‫ء‬P Ͻ 0.05, normal vs suicide.
be even less efficient in counteracting the hyperactivated state of the HPA axis.
In conclusion, both CRH-R1 and CRH-R2 are widely expressed in human tissues. The distribution differs from rodents, suggesting that results from animals cannot easily be translated to humans. Strong expression of CRH-R2 in human pituitaries and a shift in the CRH-R1/R2 ratio in pituitaries of suicide victims suggest that particularly under stress, activation of the human HPA axis can be maintained through both receptors.
